HEPAREGENIX
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a key regulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.
HEPAREGENIX
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Ulm, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.heparegenix.com
Total Employee:
1+
Status:
Active
Contact:
+49 731 2650428
Total Funding:
20 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Domain Not Resolving Apache Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Current Advisors List
Board_member
2019-09-01
Current Employees Featured
Birgit Jung Chief Scientific Officer @ HepaRegeniX
Chief Scientific Officer
Michael Lutz CEO @ HepaRegeniX
CEO
2019-10-01
Wolfgang Albrecht Co-Founder & Chief Operating Officer @ HepaRegeniX
Co-Founder & Chief Operating Officer
2019-10-01
Founder
Investors List
Ascenion GmbH
Ascenion GmbH investment in Series B - HepaRegeniX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - HepaRegeniX
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series B - HepaRegeniX
Novo Holdings
Novo Holdings investment in Series B - HepaRegeniX
coparion
coparion investment in Series B - HepaRegeniX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - HepaRegeniX
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series A - HepaRegeniX
Novo Holdings
Novo Holdings investment in Series A - HepaRegeniX
coparion
coparion investment in Series A - HepaRegeniX
Official Site Inspections
http://www.heparegenix.com
- Host name: 104.21.64.1
- IP address: 104.21.64.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "HepaRegeniX"
HepaRegeniX - Crunchbase Company Profile & Funding
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The …See details»
HepaRegeniX - HTGF
About the company Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases …See details»
HepaRegenix | Boehringer Ingelheim Venture Fund
Since 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …See details»
HepaRegeniX - 2025 Company Profile - Tracxn
Apr 26, 2025 HepaRegeniX is a series C company based in Tubingen (Germany), founded in 2017 by Stefan Laufer, Lars Zender and Wolfgang Albrecht. It operates as a Developer of …See details»
HepaRegeniX (HepaRegeniX GmbH)
HepaRegeniX GmbH erhält €9 Mio. in Serie-A-Finanzierungsrunde für die Entwicklung von Kinaseinhibitoren zur Behandlung akuter und chronischer Lebererkrankungen, High-Tech …See details»
HepaRegeniX Company Profile - Office Locations, Competitors
HepaRegeniX has 5 employees across 2 locations and $21.21 m in total funding,. See insights on HepaRegeniX including office locations, competitors, revenue, financials, executives, …See details»
HepaRegeniX GmbH – VESALIUS BIOCAPITAL IV Partners Sarl
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully …See details»
HepaRegeniX - VentureRadar
Since its inception in 2017, HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases based on a …See details»
HepaRegeniX PR
Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today …See details»
HepaRegeniX GmbH - Drug pipelines, Patents, Clinical trials
Explore HepaRegeniX GmbH with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 6 news, and 5 literature, Disease Domain:Neoplasms ...See details»
HepaRegeniX | The Pharmaletter
Oct 17, 2019 HepaRegeniX GmbH, based in Tübingen, Germany, is a clinical-stage biotechnology company developing regenerative therapies for acute and chronic liver …See details»
HepaRegeniX - Updates, News, Events, Signals & Triggers
HepaRegeniX raised €21.5 million to advance its treatments for liver diseases, indicating strong investor confidence in its biotechnology solutions. The funding was specifically allocated to …See details»
HepaRegeniX | VentureRadar
HepaRegeniX is a clinical stage company that specializes in developing a novel regenerative therapy for the treatment of acute and chronic liver diseases. The company has discovered …See details»
HTGF Series C HepaRegeniX
Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today …See details»
HepaRegeniX raises €15 million Series C round to advance clinical ...
Jul 15, 2024 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, announced the closing of a …See details»
HepaRegeniX | VentureRadar
HepaRegeniX is a clinical stage company that specializes in developing a novel regenerative therapy for the treatment of acute and chronic liver diseases. The company has discovered …See details»
HepaRegeniX completes €21.5 million financing to support clinical ...
Apr 15, 2025 HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH …See details»
HepaRegeniX - Funding, Financials, Valuation & Investors
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.See details»
HepaRegeniX (HepaRegeniX GmbH) - Startbase
Entdeckung und Entwicklung von präklinischen Arzneimittelkandidaten zur Behandlung von akuten und chronischen Leberkrankheiten auf der Basis eines neuartigen Moleküls.See details»
HepaRegeniX secures $23 million to push liver drug into Phase II
Apr 15, 2025 German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class …See details»